222 related articles for article (PubMed ID: 36867356)
1. Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma.
Shirai R; Osumi T; Keino D; Nakabayashi K; Uchiyama T; Sekiguchi M; Hiwatari M; Yoshida M; Yoshida K; Yamada Y; Tomizawa D; Takae S; Kiyokawa N; Matsumoto K; Yoshioka T; Hata K; Hori T; Suzuki N; Kato M
Int J Hematol; 2023 Jun; 117(6):910-918. PubMed ID: 36867356
[TBL] [Abstract][Full Text] [Related]
2. Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia.
Ansuinelli M; Della Starza I; Lauretti A; Elia L; Siravo V; Messina M; De Novi LA; Taherinasab A; Canichella M; Guarini A; Foà R; Chiaretti S
Hematol Oncol; 2021 Dec; 39(5):680-686. PubMed ID: 34402088
[TBL] [Abstract][Full Text] [Related]
3. A New View on Minimal Residual Disease Quantification in Acute Lymphoblastic Leukemia using Droplet Digital PCR.
Schwinghammer C; Koopmann J; Chitadze G; Karawajew L; Brüggemann M; Eckert C
J Mol Diagn; 2022 Aug; 24(8):856-866. PubMed ID: 35691569
[TBL] [Abstract][Full Text] [Related]
4. Droplet Digital PCR Is a Robust Tool for Monitoring Minimal Residual Disease in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia.
Coccaro N; Anelli L; Zagaria A; Casieri P; Tota G; Orsini P; Impera L; Minervini A; Minervini CF; Cumbo C; Parciante E; Carluccio P; Brunetti C; Specchia G; Albano F
J Mol Diagn; 2018 Jul; 20(4):474-482. PubMed ID: 29625246
[TBL] [Abstract][Full Text] [Related]
5. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM; Kneba M
Methods Mol Biol; 2019; 1956():199-228. PubMed ID: 30779036
[TBL] [Abstract][Full Text] [Related]
6. Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma.
Subhash VV; Huang L; Kamili A; Wong M; Chen D; Venn NC; Atkinson C; Mayoh C; Venkat P; Tyrrell V; Marshall GM; Cowley MJ; Ekert PG; Norris MD; Haber M; Henderson MJ; Sutton R; Fletcher JI; Trahair TN
Br J Cancer; 2022 Feb; 126(3):482-491. PubMed ID: 34471258
[TBL] [Abstract][Full Text] [Related]
7. Transferring measurable residual disease measurement in pediatric acute lymphoblastic leukemia from quantitative real-time PCR to digital droplet PCR.
Luib L; Kreyenberg H; Michaelis S; Handgretinger R; Mezger M
Pediatr Transplant; 2023 Jun; 27(4):e14483. PubMed ID: 36750990
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
Shahkarami S; Mehrasa R; Younesian S; Yaghmaie M; Chahardouli B; Vaezi M; Rezaei N; Nikbakht M; Alimoghaddam K; Ghavamzadeh A; Tavakkoly-Bazzaz J; Ghaffari SH
Ann Hematol; 2018 Apr; 97(4):585-595. PubMed ID: 29392424
[TBL] [Abstract][Full Text] [Related]
9. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.
Pongers-Willemse MJ; Verhagen OJ; Tibbe GJ; Wijkhuijs AJ; de Haas V; Roovers E; van der Schoot CE; van Dongen JJ
Leukemia; 1998 Dec; 12(12):2006-14. PubMed ID: 9844931
[TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease quantification in childhood acute lymphoblastic leukemia by real-time polymerase chain reaction using the SYBR green dye.
Li AH; Forestier E; Rosenquist R; Roos G
Exp Hematol; 2002 Oct; 30(10):1170-7. PubMed ID: 12384148
[TBL] [Abstract][Full Text] [Related]
11. How I investigate minimal residual disease in acute lymphoblastic leukemia.
Correia RP; Bento LC; de Sousa FA; Barroso RS; Campregher PV; Bacal NS
Int J Lab Hematol; 2021 Jun; 43(3):354-363. PubMed ID: 33423385
[TBL] [Abstract][Full Text] [Related]
12. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
Gaipa G; Basso G; Biondi A; Campana D
Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
[TBL] [Abstract][Full Text] [Related]
13. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.
Nunes V; Cazzaniga G; Biondi A
Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia.
Della Starza I; Nunes V; Cavalli M; De Novi LA; Ilari C; Apicella V; Vitale A; Testi AM; Del Giudice I; Chiaretti S; Foà R; Guarini A
Br J Haematol; 2016 Aug; 174(4):541-9. PubMed ID: 27172403
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL.
Garand R; Beldjord K; Cavé H; Fossat C; Arnoux I; Asnafi V; Bertrand Y; Boulland ML; Brouzes C; Clappier E; Delabesse E; Fest T; Garnache-Ottou F; Huguet F; Jacob MC; Kuhlein E; Marty-Grès S; Plesa A; Robillard N; Roussel M; Tkaczuk J; Dombret H; Macintyre E; Ifrah N; Béné MC; Baruchel A
Leukemia; 2013 Feb; 27(2):370-6. PubMed ID: 23070018
[TBL] [Abstract][Full Text] [Related]
17. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.
van der Velden VH; Cazzaniga G; Schrauder A; Hancock J; Bader P; Panzer-Grumayer ER; Flohr T; Sutton R; Cave H; Madsen HO; Cayuela JM; Trka J; Eckert C; Foroni L; Zur Stadt U; Beldjord K; Raff T; van der Schoot CE; van Dongen JJ;
Leukemia; 2007 Apr; 21(4):604-11. PubMed ID: 17287850
[TBL] [Abstract][Full Text] [Related]
18. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping.
Malec M; van der Velden VH; Björklund E; Wijkhuijs JM; Söderhäll S; Mazur J; Björkholm M; Porwit-MacDonald A
Leukemia; 2004 Oct; 18(10):1630-6. PubMed ID: 15295608
[TBL] [Abstract][Full Text] [Related]
19. Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia.
Mai H; Li Q; Wang G; Wang Y; Liu S; Tang X; Chen F; Zhou G; Liu Y; Li T; Wang L; Wang C; Wen F; Liu S
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3259-3266. PubMed ID: 35918464
[TBL] [Abstract][Full Text] [Related]
20. [Detection of minimal residual disease in childhood acute lymphoblastic leukemia by using real-time quantitative PCR].
Zhang YT; Luo ZF; Fang JP; Guo HX; Huang K; Li CK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1235-9. PubMed ID: 21129267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
